Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiac Science Inc. DFIB (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Marc Phelan who wrote (64)	3/2/2002 9:48:16 AM
From: Harry J.	Read Replies (1) \| Respond to of 174

Marc - Yes, it does. Positive qtrly results came out 27 Feb so, naturally, the stock dropped. 8-) Click on "News" or read this cut-and-paste. On the other hand, with $15.8 mill in cash and a recent qtrly loss of $5.8 mill, does this mean they (grossly, anyway) have less than a year's operating cash on hand? Maintaining the 46% gross margins, if they can, (which is up from 7% a year ago) may help stretch this out. (Guess I should say "we" as I have a small, long term stake in CardSci.) Regards, Harry J. == Cardiac Science Announces Fourth Quarter, Year End Results Strong AED Sales, Growth in Disposable Sales to Hospitals Highlight The Quarter IRVINE, Calif., Feb 27, 2002 /PRNewswire-FirstCall via COMTEX/ -- Cardiac Science, Inc. (Nasdaq: DFIB chart, msgs), today reported that the positive impact of public access defibrillator (AED) sales from the acquisition of Survivalink(R) along with international sales of Artema(R) emergency defibrillators and patient monitors resulted in a 420 percent jump in revenue to $7.8 million in the fourth quarter ended December 31, 2001, up from $1.5 million in revenue posted in the same period last year. The net loss for the fourth quarter was $5.8 million, or $0.10 loss per share, compared to $7.4 million, or $0.30 loss per share posted in the fourth quarter of 2000. The balance sheet at December 31, 2001 showed cash and cash equivalents totaling $15.8 million. In the fourth quarter of 2001, domestic sales accounted for approximately 70 percent of total Company revenue with the balance coming from sales to international distributors. AED sales for the fourth quarter of 2001 totaled $6.2 million or approximately 80 percent of total revenue. Sales of Powerheart(R) disposable defibrillator pads to U.S. hospitals for this period grew by 560 percent to $180,000 compared to $27,000 posted in last year's corresponding period. For the year ended December 31, 2001, revenue more than doubled to $10.7 million versus $4.2 million in 2000. The net loss the year narrowed to $26.2 million, or $0.78 loss per share, from a net loss of $32.9 million, or $1.82 loss per share in 2000. Sales of Powerheart(R) disposable defibrillator pads for 2001 grew by more than 500 percent to $495,000 from $82,000 posted in the year 2000. Gross profit margins for the fourth quarter were 46 percent as compared to 7 percent for the same period in 2000. This strong upward trend in margins is primarily attributable to the sales of AEDs and the increased level of high- margin recurring revenue from the sale of Powerheart(R) disposable defibrillator pads. [snip - DFIB's safe harbor & contact info which appeared in the PR.]